OakChart

Integra Lifesciences Holdings Corp

IARTHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 12:02 PM ET

14.55+0.02 (0.14%)
2026-11-11 18:03 CET
Market cap
1,130.45 USD m
Revenue, TTM
1,656.79 USD m
Net income, TTM
13.01 USD m
Free cash flow, TTM
85.78 USD m
EPS diluted, TTM
0.16
P/E
88.45
Compare

Price

IART against its 20, 50 and 200-day averages
2050200beat
10.0012.5015.0017.5020.001.3M2.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IARTclose 14.5520-day 13.2350-day 14.41200-day 14.1514.5552w high

29.0% under the 52-week high of 20.49 on 28 Jul 2026. 52-week low 8.70 on 20 Mar 2026. Last 15 sessions, 30.8% high to low

Profile

IART
52-week range, 50% of the way up
8.7020.49

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

IndexRUT
Employees4427
IPOAug 16, 1995
Beta1.26
ATR, 14d0.82
Rel volume0.59
Short float11.87%
Insider own14.48%
Inst own96.14%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.13B
Enterprise Value2.82B
Income13.01M
Sales1.66B
Book/sh13.71
Cash/sh4.01
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees4427
IPOAug 16, 1995

Ratios

P/E88.45
Forward P/E6.14
PEG1.77
P/S0.68
P/B1.06
P/C3.63
P/FCF13.20
EV/EBITDA8.14
EV/Sales1.70
Quick Ratio2.21
Current Ratio3.62
Debt/Eq1.88
LT Debt/Eq1.82
Option/ShortYes / Yes

Earnings

EPS (ttm)0.16
EPS next Y2.37
EPS next Q0.64
EPS this Y4.71%
EPS next Y1.49%
EPS next 5Y3.46%
EPS past 3/5Y- -
Sales past 3/5Y1.63% 3.57%
EPS Y/Y TTM102.60%
Sales Y/Y TTM0.84%
EPS Q/Q368.47%
Sales Q/Q2.27%
EarningsOct 21 BMO
EPS/Sales Surpr.5.85% -0.48%

Ownership

Insider Own14.48%
Insider Trans0.00%
Inst Own96.14%
Inst Trans-0.14%
ROA0.36%
ROE1.24%
ROIC0.43%
Gross Margin54.85%
Oper. Margin11.63%
Profit Margin0.79%
SMA2010.00%
SMA500.98%
SMA2002.82%
Trades-

Technical

Shs Outstand77.81M
Shs Float66.54M
Short Float11.87%
Short Ratio7.85
Short Interest7.90M
52W High20.49 -28.99%
52W Low8.70 67.24%
Volatility8.21% 6.07%
ATR (14)0.82
RSI (14)56.14
Beta1.26
Rel Volume0.59
Avg Volume1.01M
Volume249,506

Performance

Perf Week-1.82%
Perf Month5.05%
Perf Quarter-20.23%
Perf Half Y-2.35%
Perf YTD17.15%
Perf Year18.00%
Perf 3Y-59.76%
Perf 5Y-78.57%
Perf 10Y-63.47%
Recom2.75
Target Price15.67
Prev Close14.53
Price14.55
Change %0.14%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jul 28, 2026InitiatedUUBSNeutral$19+30.6%
Jul 09, 2026InitiatedBBMO Capital MarketsMarket Perform$19+30.6%
Jun 18, 2026UpgradeAArgusHold → Buy$25+71.8%
May 28, 2026UpgradeCCitigroupSell → Neutral$16+10.0%
Apr 15, 2026DowngradeAArgusBuy → Hold
Mar 31, 2025UpgradeAArgusHold → Buy
Dec 02, 2024InitiatedMMorgan StanleyUnderweight$25 → $20+37.5%
Oct 07, 2024UpgradeBBTIG ResearchSell → Neutral
Jul 30, 2024DowngradeCCitigroupNeutral → Sell$30 → $23+58.1%
Jul 30, 2024DowngradeBBTIG ResearchNeutral → Sell$22+51.2%

Peers

Mkt cap
TickerCompanyMkt cap
SNNSmith & Nephew plc ADR12.91B
MDTMedtronic Plc129.31B
RCELAVITA Medical Inc430.38M
MDXGMimedx Group Inc490.31M
SYKStryker Corp121.12B
CLPTClearPoint Neuro Inc290.74M
CNMDConmed Corp1.51B
ORGOOrganogenesis Holdings Inc129.59M
AORTArtivion Inc1.00B
ANIKAnika Therapeutics Inc185.79M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 11 '26Option Exercise0.0018,922040,612Mar 12 06:10 PM
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 10 '26Option Exercise0.001,216023,152Mar 12 06:10 PM
Poul MojdehPresident & CEOJan 06 '26Option Exercise0.001,39001,390Jan 07 04:10 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
DFSVUS Small Cap Value Portfolio ETF Class Shares-
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
IJSiShares S&P Small-Cap 600 Value ETFAUM: 7.74B

News

latest 14 of 204
  • Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference (GlobeNewswire)
  • Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting (GlobeNewswire)
  • Integra LifeSciences Edges Past EPS Consensus, But The Cincinnati Flood And Weak Tissue Reconstruction Drive A Guidance Reset (Earnings Whispers) -11.18%
  • Integra: Q3 Earnings Snapshot (Associated Press)
  • Integra LifeSciences Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Loading…
  • Integra Announces Completion of Refinancing Transactions (GlobeNewswire)
  • Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting (GlobeNewswire)
  • Integra Announces Pricing of Senior Secured Notes (GlobeNewswire)
  • Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026 (GlobeNewswire)
  • Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for Direction (PR Newswire)
  • Integra LifeSciences lowers revenue and earnings outlook for 2026 (Proactive) -21.19%
  • Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance (GlobeNewswire)
  • Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-210.5900.5570.190411.18413.1611
2026Q22026-07-290.5600.4810.057418.76417.5411
2026Q12026-05-050.5400.405-0.060391.92381.818
2025Q42026-02-260.8300.800-0.022434.93429.639
2025Q32025-10-300.5400.434-0.070402.06414.239
2025Q22025-07-310.4500.436-6.312415.6139510
2025Q12025-05-050.4100.431-0.331382.65381.210
2024Q42025-02-250.9700.8540.252442.65445.1110
2024Q32024-11-040.4100.390-0.140380.83375.8111
2024Q22024-07-290.6300.624-0.160418.18413.0711
2024Q12024-05-060.5500.552-0.042368.87363.7411
2023Q42024-02-280.8900.9030.253397.04399.3411
2023Q32023-10-250.7600.7780.244382.42387.2211
2023Q22023-07-260.7100.5690.052381.27374.019
2023Q12023-04-260.7400.7380.294380.85373.2311
2022Q42023-02-220.9400.9040.633398.02397.9211

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY2.4202.3910.7241,4721,470
2019FY2.7402.7380.5801,5181,520
2020FY2.4502.3541.5711,3721,372
2021FY3.1803.1771.9781,5421,540
2022FY3.3603.3132.1621,5581,558
2023FY3.1003.1070.8431,5421,544
2024FY2.5602.452-0.0901,6111,613
2025FY2.2302.201-6.7401,6351,630
2026FY-2.335--1,644
2027FY-2.370--1,675
2028FY-2.470--1,734
2029FY-3.000--1,807

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-2211011422.37420.1424
2026Q4S2026-10-2111010424.11420.1441.89
2026Q4S2026-10-151106434.64422.3449.32
2026Q4S2026-10-141105436.92422.31453.4
2026Q4S2026-10-131104439.02423.72453.4
2026Q4S2026-10-121103441.24424.24453.4
2026Q4S2026-10-091115441.24424.24453.4
2026Q4S2026-10-051115441.24424.24453.4
2026Q4S2026-10-021114443.17426.6453.4
2026Q4S2026-10-011113445.66428453.9
2026Q4S2026-09-301112447.4441.89453.9
2026Q4S2026-08-191112447.4441.89453.9
2026Q4S2026-07-301112447.4441.89453.9
2026Q4S2026-07-291112447.37441.89453.9

Estimate history

EPS, annual0.820.7240.581.5711.9782.1620.843-0.09-6.7360.1645
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.140.252-0.331-6.312-0.07-0.022-0.060.0570.189
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1188.2361472.4411517.5571371.8681542.4481557.6661541.5731610.5271635.2451656.79
Period201720182019202020212022202320242025TTM
Sales, quarterly380.834442.645382.653415.605402.062434.925391.918418.761411.182
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual78.39485.16385.8784.33784.70183.65478.16977.16577.88777.806
Period201720182019202020212022202320242025MRQ
Shares, quarterly77.13477.16577.71277.92177.83577.88777.81877.77977.806
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,656.791,635.241,610.531,541.571,557.671,542.451,371.871,517.561,472.44
Cost of Goods Sold Incl. D&A747.97773.39711.77647.37629.61655.84562.48612.45558.09
Gross Profit908.82861.86898.75894.21928.05886.60809.39905.11914.35
Selling, General and Administrative Excl. Other716.13679.60715.99633.54655.25611.08595.95653.41679.50
Research and Development70.2734.8154.4341.9441.4236.2331.1733.0878.04
Other Operating Expense0.000.000.0040.030.000.000.000.000.00
Operating Income192.68182.26182.76220.63272.81275.52213.44251.70234.85
Interest Expense110.4198.8788.0969.4342.2327.9855.4356.2367.94
Unusual Expense106.12678.87153.56108.689.57-2.0189.94155.44124.64
Net Income Before Taxes22.31-563.50-18.2481.07213.89214.6893.5260.1057.40
Income Taxes9.30-47.03-11.2913.3333.3445.60-40.379.90-3.40
Consolidated Net Income13.01-516.47-6.9467.74180.55169.07133.8950.2060.80
Net Income From Continuing Operations13.01-516.47-6.9467.74180.55169.07133.8950.2060.80
Net Income13.01-516.47-6.9467.74180.55169.07133.8950.2060.80
EPS (Recurring)1.11-0.541.311.792.241.962.311.841.76
EPS (Basic, Before Extraordinaries)0.17-6.74-0.090.852.182.001.580.590.73
EPS (Diluted)0.16-6.74-0.090.842.161.981.570.580.72
EBITDA346.52334.09323.26344.15391.10399.19332.43366.39350.55
Non-Operating Income (Expense)46.1531.9840.6538.55-7.11-34.8825.4520.0715.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense16.6415.7619.7014.9213.5522.4113.3711.8410.35
Price To Earnings Ratio88.3388.33-35.6127.3033.8641.19100.6962.17
Price To Sales Ratio0.770.581.082.273.013.714.033.322.57
Gross Margin54.8552.7155.8058.0159.5857.4859.0059.6462.10
Operating Margin11.6311.1511.3514.3117.5117.8615.5616.5915.95
Net Margin0.79-31.58-0.434.3911.5910.969.763.314.13
Shares Outstanding77.8177.8977.1778.1783.6584.7084.3485.8785.16
Market Capitalization1,130.451,130.451,750.073,404.564,682.875,674.025,470.985,004.273,841.62

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue411.18418.76391.92434.93402.06415.61382.65442.64
Cost of Goods Sold Incl. D&A186.57188.98167.68204.73175.95189.61171.23190.95
Gross Profit224.61229.78224.24230.19226.11226.00211.42251.69
Selling, General and Administrative Excl. Other182.54185.25184.15164.19200.26190.40162.48188.67
Research and Development22.1121.7418.697.7420.4221.4521.2213.35
Other Operating Expense0.000.000.000.000.000.0014.810.00
Operating Income42.0744.5340.0866.0025.8535.5934.1363.02
Interest Expense27.4427.3326.8428.8027.3522.4820.2422.05
Unusual Expense14.2725.2429.5437.0714.76550.2723.2232.42
Net Income Before Taxes15.664.74-2.414.31-6.82-530.95-30.0422.54
Income Taxes0.810.262.216.01-1.42-46.88-4.743.11
Consolidated Net Income14.854.48-4.62-1.70-5.40-484.07-25.2919.43
Net Income From Continuing Operations14.854.48-4.62-1.70-5.40-484.07-25.2919.43
Net Income14.854.48-4.62-1.70-5.40-484.07-25.2919.43
EPS (Recurring)0.320.280.210.310.06-1.29-0.120.55
EPS (Basic, Before Extraordinaries)0.190.06-0.06-0.02-0.07-6.31-0.330.25
EPS (Diluted)0.190.06-0.06-0.02-0.07-6.31-0.330.25
EBITDA81.1382.6678.51104.2164.2773.2971.31100.51
Non-Operating Income (Expense)15.3112.7813.894.179.446.20-20.7013.99
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.294.713.985.664.414.221.475.59
Price To Earnings Ratio88.33-------
Price To Sales Ratio0.770.850.440.590.670.581.041.09
Gross Margin54.6354.8757.2252.9356.2454.3855.2556.86
Operating Margin10.2310.6310.2315.186.438.568.9214.24
Net Margin3.611.07-1.18-0.39-1.34-116.47-6.614.39
Shares Outstanding77.8177.7877.8277.8977.8377.9277.7177.17
Market Capitalization1,130.451,397.23734.17967.421,116.46953.531,698.041,750.07

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments263.74273.57309.10456.66513.45470.17198.91138.84174.94
Short Term Receivables285.69272.37259.33273.59243.24232.96283.98269.93251.80
Inventories492.74429.09389.61324.58317.39310.12316.05280.35296.33
Other Current Assets117.38106.65100.00106.6779.64223.9659.2385.9799.08
Total Current Assets1,159.541,081.681,058.041,161.501,153.721,237.20858.17775.08822.15
Net Property, Plant & Equipment584.90549.76496.38459.59396.25371.16431.93300.11269.25
Total Investments and Advances12.7838.3032.1843.346.480.003.467.120.00
Intangible Assets1,749.822,304.542,123.302,165.492,159.031,921.801,985.872,005.972,097.53
Deferred Tax Assets69.8534.9246.0845.9956.9573.6912.626.806.25
Other Assets25.1028.2126.0113.859.9611.2811.1812.7916.08
Total Assets3,602.004,037.423,781.993,889.763,782.383,615.143,303.243,107.893,211.26
Short Term Debt Incl. Current Port. of LT Debt140.57621.6229.8252.7559.77159.0757.2522.5060.00
Accounts Payable95.7382.5092.33102.1061.8454.61113.0976.0593.97
Income Tax Payable3.65--------
Other Current Liabilities216.03218.01184.84166.06218.41187.34160.97164.00194.94
Total Current Liabilities455.98922.13306.98320.91340.02401.01331.31262.55348.91
Long Term Debt1,892.621,362.951,651.871,562.611,591.511,496.341,400.571,331.711,781.14
Provision for Risks Charges13.8415.4419.3812.310.000.000.0021.6722.11
Deferred Tax Liabilities5.6660.8335.3263.3445.7916.1936.5557.7865.13
Other Liabilities190.44130.79180.56126.19120.26186.73118.0858.3831.66
Total Liabilities2,558.542,492.142,194.102,085.362,097.582,100.271,886.501,732.092,248.95
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,043.461,545.281,587.881,804.401,684.801,514.871,416.741,375.80962.31
Total Shareholders Equity1,043.461,545.281,587.881,804.401,684.801,514.871,416.741,375.80962.31
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,043.461,545.281,587.881,804.401,684.801,514.871,416.741,375.80962.31
Total Liabilities & Stockholders Equity3,602.004,037.423,781.993,889.763,782.383,615.143,303.243,107.893,211.26
Book Value Per Share13.4020.0320.3121.5719.8917.9616.5016.1512.28
Tangible Book Value Per Share-9.07-9.84-6.85-4.32-5.60-4.83-6.63-7.40-14.48
Full-Time Employees4,4274,3965,3293,7223,8003,7004,0004,5004,400
Price to Book Ratio1.061.152.182.723.373.613.532.794.11
Return on Assets-13.52-0.181.774.714.573.871.571.922.58
Return on Equity-39.90-0.443.9910.3510.579.133.605.207.19
Return on Invested Capital-17.59-0.242.095.365.164.451.782.252.36
Quick Ratio1.460.712.182.612.462.311.641.881.51
Current Ratio2.541.173.453.623.393.092.592.952.36

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income13.01-516.47-6.9467.74180.55169.07133.8950.2060.80
Depreciation154.06151.83140.89123.51118.30123.67118.99114.52110.73
Other Funds (Non Cash)21.49515.0347.1742.169.624.2756.41100.2729.55
Funds from Operations175.3184.12160.39221.53303.89294.26245.15245.94192.90
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-34.91-33.74-31.01-81.57-39.4218.16-41.31-14.511.75
Cash from Operating Activities140.4050.38129.38139.96264.47312.43203.83231.43194.65
Capital Expenditures-68.82-95.64-114.37-66.86-47.09-48.08-63.89-134.53-77.74
Net Assets From Acquisitions0.000.00-277.810.00-51.51-303.910.00-30.510.00
Sale of Fixed Assets and Businesses0.000.000.000.0035.10190.473.660.0427.13
Purchase or Sale of Investments-23.98-1.505.50-32.690.000.000.000.000.00
Purchase of Investments-30.98-8.50-49.00-32.690.000.000.000.000.00
Sale Or Maturity of Investments7.007.0054.500.000.000.000.000.000.00
Other Uses-10.49-10.92-4.130.000.000.00-7.840.000.00
Other Sources0.000.000.005.384.910.080.002.340.91
Cash from Investing Activities-103.28-108.06-390.81-94.18-58.58-161.44-68.07-162.67-49.70
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.760.74-46.07-270.68-119.536.82-50.206.95358.98
Repurchase of Common Pref Stock0.00-0.22-52.47-275.00-125.000.00-100.000.000.00
Sale of Common Pref Stock0.760.966.404.325.466.8249.806.95358.98
Proceedsfrom Stock Options0.000.000.000.000.000.0044.560.00349.59
Issuance or Reduction of Debt, Net-6.4646.75299.3746.62-107.80-100.25281.15-9.20-488.80
Change in Long Term Debt-6.4646.75299.3746.62-107.80-100.25281.15-9.20-488.80
Issuance of Long Term Debt145.09716.64486.50157.2240.7525.25722.15236.90171.20
Reduction of Long Term Debt-151.55-669.89-187.13-110.60-148.55-125.50-441.00-246.10-660.00
Net Financing Active Other Cash Flow-8.77-19.15-15.43-5.86-24.62-4.80-109.32-6.51-46.02
Other Financing Activities Uses-8.77-19.15-15.43-5.86-24.62-4.80-109.32-6.51-46.02
Cash from Financing Activities-14.4728.34237.86-229.93-251.95-98.23121.62-8.77-175.84
Exchange Rate Effect-2.5718.02-6.463.89-10.72-9.4813.870.07-5.20
Net Change in Cash20.07-11.33-30.03-180.26-56.7943.28271.2560.07-36.10
Free Cash Flow85.78-31.0524.9673.09222.13264.40164.94161.90116.91
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow14.91-69.9647.8721.0821.6633.5531.1432.41
Deferred Taxes & Investment Tax Credit--66.26-20.73-11.88-4.58-2.75-64.14-19.05-8.18

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments311.93274.08265.50263.74267.88253.61
Short Term Receivables248.99267.19271.07285.69262.16284.51
Inventories464.45492.00495.04492.74489.11465.13
Other Current Assets164.56158.21140.41117.38124.44139.59
Total Current Assets1,189.941,191.481,172.021,159.541,143.581,142.83
Net Property, Plant & Equipment577.27583.29584.08584.90575.55571.39
Total Investments and Advances6.349.6512.1512.7815.5418.50
Intangible Assets1,648.461,686.691,718.591,749.821,775.341,804.51
Deferred Tax Assets66.7170.4468.0869.85109.73102.94
Other Assets19.0721.9422.8125.1026.7127.74
Total Assets3,507.803,563.493,577.733,602.003,646.453,667.91
Short Term Debt Incl. Current Port. of LT Debt63.0357.5152.68140.5752.58627.55
Accounts Payable66.4282.6487.9595.7392.3192.83
Income Tax Payable1.703.243.243.65--
Other Current Liabilities197.85187.49202.98216.03219.17209.42
Total Current Liabilities329.00330.88346.85455.98364.05929.81
Long Term Debt1,939.241,991.371,986.771,892.621,953.281,386.21
Provision for Risks Charges0.000.000.0013.840.000.00
Deferred Tax Liabilities4.793.476.145.6658.2860.06
Other Liabilities168.14194.40195.56190.44233.25253.16
Total Liabilities2,441.182,520.112,535.322,558.542,608.882,629.24
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,066.621,043.381,042.411,043.461,037.571,038.66
Total Shareholders Equity1,066.621,043.381,042.411,043.461,037.571,038.66
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,066.621,043.381,042.411,043.461,037.571,038.66
Total Liabilities & Stockholders Equity3,507.803,563.493,577.733,602.003,646.453,667.91
Book Value Per Share13.7113.4113.4013.4013.3313.33
Tangible Book Value Per Share-7.48-8.27-8.69-9.07-9.48-9.83
Full-Time Employees---4,427--
Price to Book Ratio1.061.340.700.931.070.63
Return on Assets0.36-0.20-13.00-13.52-12.85-12.93
Return on Equity1.24-0.70-38.64-39.90-38.71-38.92
Return on Invested Capital0.490.15-0.15-0.06-0.18-19.96
Quick Ratio2.212.111.951.461.800.73
Current Ratio3.623.603.382.543.141.23

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income14.854.48-4.62-1.70-5.40-484.07
Depreciation39.0638.1338.4338.4338.5237.69
Other Funds (Non Cash)4.1710.645.291.39-7.86518.16
Funds from Operations58.7948.9340.4327.1616.6126.95
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital37.19-26.13-30.62-15.3524.30-18.03
Cash from Operating Activities95.9822.809.8011.8240.918.92
Capital Expenditures-10.25-12.31-14.85-31.42-15.16-20.15
Net Assets From Acquisitions0.000.000.000.00--
Sale of Fixed Assets and Businesses0.000.000.000.00--
Purchase or Sale of Investments0.00-30.980.007.000.00-1.50
Purchase of Investments0.00-30.980.000.000.00-1.50
Sale Or Maturity of Investments0.000.000.007.000.000.00
Other Uses0.000.000.00-10.49-0.430.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-10.25-43.28-14.85-34.91-15.59-21.65
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.760.000.00-0.22
Repurchase of Common Pref Stock0.000.000.000.000.00-0.22
Sale of Common Pref Stock0.000.000.760.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-46.096.248.9124.48-10.05-6.84
Change in Long Term Debt-46.096.248.9124.48-10.05-6.84
Issuance of Long Term Debt19.9031.1244.5049.57603.629.04
Reduction of Long Term Debt-65.99-24.89-35.59-25.09-613.67-15.89
Net Financing Active Other Cash Flow-0.20-7.06-1.38-0.14-0.20-14.08
Other Financing Activities Uses-0.20-7.06-1.38-0.14-0.20-14.08
Cash from Financing Activities-46.29-0.828.3024.34-10.24-21.14
Exchange Rate Effect-1.60-1.09-1.491.61-0.8012.68
Net Change in Cash37.85-22.391.762.8614.27-21.19
Free Cash Flow85.7310.49-5.04-5.4025.75-11.23
Price to Free Cash Flow14.9154.41177.67---

Revenue breakdown

ENT2024: 135.64M 2025: 166.37M
Instruments2024: 204.18M 2025: 206.47M
Neurosurgery2024: 803.82M 2025: 827.67M
Private Label2024: 116.33M 2025: 111.25M
Regenerative Skin And Wound2024: 350.57M 2025: 323.49M
Asia Pacific2024: 176.61M 2025: 189.25M
Europe2024: 158.50M 2025: 162.67M
Rest Of The World2024: 82.74M 2025: 78.58M
United States2024: 1.19B 2025: 1.20B
Codman Specialty Surgical2024: 1.14B 2025: 1.20B
Tissue Technologies2024: 466.89M 2025: 434.73M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.87%7.9M66.5M950.07K
2026-10-1511.00%7.3M66.5M929.58K
2026-09-3010.93%7.3M66.5M848.62K
2026-09-1510.23%6.8M66.5M870.51K
2026-08-3110.31%6.9M66.5M871.73K
2026-08-1410.13%6.7M66.6M944.11K
2026-07-319.73%6.5M66.6M1.09M
2026-07-159.32%6.2M66.6M1.02M
2026-06-309.61%6.4M66.6M1.00M
2026-06-1510.86%7.2M66.5M957.93K
2026-05-2912.00%8.0M66.6M970.21K
2026-05-1513.83%9.2M66.6M945.65K
2026-04-3014.02%9.3M66.5M803.75K
2026-04-1513.76%9.2M66.6M799.11K
2026-03-3113.28%8.9M66.7M785.30K
2026-03-1312.54%8.4M66.7M758.88K
2026-02-2711.21%7.5M66.7M736.18K
2026-02-1311.39%7.6M66.6M754.43K
2026-01-3011.58%7.6M65.9M848.88K
2026-01-1511.28%7.4M65.9M944.93K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5011.1013.700.0017.8090.000.000.992-0.0170.001
call5.008.1011.200.009.9470.000.000.932-0.1280.003
call7.505.608.700.006.6190.000.000.890-0.1250.004
call10.003.106.200.004.6260.000.000.832-0.1120.006
call12.501.852.602.001.53117.001.000.735-0.0900.008
call15.000.001.350.631.67721.000.000.517-0.0920.009
call17.500.000.950.152.09715.000.000.349-0.0990.008
call20.000.002.150.032.7071.000.000.298-0.1190.008
call22.500.000.500.002.5360.000.000.187-0.0870.006
call25.000.002.150.002.9050.000.000.171-0.0940.006
call30.000.002.150.003.5040.000.000.151-0.1040.005
put2.500.000.050.005.5350.000.00-0.008-0.0150.001
put5.000.002.150.007.6580.000.00-0.068-0.1270.003
put7.500.000.950.005.1830.000.00-0.111-0.1240.004
put10.000.002.150.103.49947.000.00-0.168-0.1110.006
put12.500.000.950.502.10525.000.00-0.270-0.0870.008
put15.000.352.101.202.04411.000.00-0.483-0.0910.009
put17.502.203.400.001.5100.000.00-0.651-0.0970.008
put20.003.906.900.003.3300.000.00-0.702-0.1170.008
put22.506.309.400.003.8540.000.00-0.813-0.0840.006
put25.009.6011.100.003.1950.000.00-0.829-0.0910.006
put30.0013.7016.700.004.7260.000.00-0.850-0.1010.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-10-2310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-218-KCurrent report2026-10-21SEC
2026-10-198-KCurrent report2026-10-19SEC
2026-10-133Initial statement of beneficial ownership of securities2026-10-01SEC
2026-10-098-KCurrent report2026-10-09SEC
2026-10-028-KCurrent report2026-10-02SEC
2026-09-283Initial statement of beneficial ownership of securities2026-09-17SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-13SCHEDULE 13G/ASEC
2026-07-31SCHEDULE 13GSEC
2026-07-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-298-KCurrent report2026-07-29SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-03SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-29SDSpecialized Disclosure ReportSEC
2026-05-15SCHEDULE 13GSEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-08S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-088-KCurrent report2026-05-07SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-11102.15K100

Institutional holders

Manager% owned
BlackRock, Inc.13.73%
Rubric Capital Management LP9.97%
Invesco Ltd.4.82%
VANGUARD PORTFOLIO MANAGEMENT LLC4.81%
MORGAN STANLEY4.62%
PARADIGM CAPITAL MANAGEMENT INC/NY4.42%
FULLER & THALER ASSET MANAGEMENT, INC.4.42%
STATE STREET CORP3.79%
VANGUARD CAPITAL MANAGEMENT LLC3.79%
DIMENSIONAL FUND ADVISORS LP3.56%

Funds

Fund% owned
iShares Core S&P Small-Cap ETF5.18%
Invesco Small Cap Value Fund4.36%
Undiscovered Managers Behavioral Value Fund3.63%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.71%
iShares Russell 2000 ETF2.29%
VANGUARD SMALL-CAP INDEX FUND1.95%
VANGUARD SMALL-CAP VALUE INDEX FUND1.23%
Small Cap Equity Portfolio1.08%
VANGUARD EXTENDED MARKET INDEX FUND0.99%
Fidelity Small Cap Index Fund0.96%

OakChart. IART. Cached 15 minutes.